The FDA approved a HER2-targeted therapy for the treatment of breast tumors with low HER2 expression. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients...
Study finds majority of patients treated with chemotherapy experience hearing loss, and more from this week in cancer news.
The FDA approved darolutamide for the treatment of metastatic prostate cancer that is sensitive to hormone-blocking treatment. The U.S. Food and Drug Administration (FDA) has approved darolutamide (Nubeqa), in combination with the chemotherapy docetaxel,...
Cancer patients and doctors concerned about how abortion bans will affect treatment, and resistant starch supplements lower risk of many cancers in people with Lynch syndrome.
Clinical outcomes are similar between Black and non-Black patients when patients receive identical treatment and follow-up in a highly structured study environment, researchers say. When Black patients were included in proportion to the larger...
Drug shortages in hematology oncology and more from the week in cancer news, as selected by the editors of Cancer Today magazine.
A new study adds nuance to the ‘golden age’ of cancer drug approvals.
COVID-19 boosters promote immune response in additional blood cancer patients, and high drug costs lead cancer patients to not fill prescriptions.
The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S. Food and Drug Administration has approved crizotinib (Xalkori) for the treatment of certain patients 1...
People in treatment for early-stage cancer should try to get exercise, according to new recommendations.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More